文献速递老年综合评估认知障碍与谵妄衰弱、肌少症与跌倒

阿尔茨海默病血液生物标志物的新突破:老年人群中的机遇与挑战

Recent breakthroughs in blood-based biomarkers of Alzheimer disease: opportunities and challenges in older adults.
PubMed 文献 · Age Ageing · 2026-01-01

本文评述血浆p-tau217等血液生物标志物(BBMs)在阿尔茨海默病(AD)诊断中的进展,指出其在检测淀粉样蛋白病理方面表现稳定。老年人群多病共存、慢性肾病、多重用药和衰弱可能影响标志物绝对浓度,但诊断性能基本保持。建议将BBMs整合到老年综合评估框架中,仅用于有症状的老年专科就诊者。

要点

  • 血浆p-tau217在多平台对淀粉样蛋白病理检测显示稳定强诊断性能。
  • 衰弱可能改变AD病理与轻度认知障碍/痴呆临床表达的关系及BBMs绝对浓度。
  • BBMs应整合到老年综合评估框架,仅用于有症状的老年专科就诊者。

核心结论

  • 血浆p-tau217是高度准确且可扩展的AD病理诊断标志物。
  • 老年人群多病共存、慢性肾病、多重用药和衰弱可能影响BBMs绝对浓度,但p-tau217诊断性能基本保持。
  • BBMs的临床价值在于与适合老年医学的诊断路径整合,而非单独使用。

研究设计与样本

  • 本文为评论性文章,评述BBMs性能进展、新兴临床指南、真实世界证据及老年相关诊断陷阱。

主要发现

  • 血浆p-tau217在多个分析平台上对淀粉样蛋白病理检测显示一致强诊断性能。
  • 衰弱可能改变AD病理与轻度认知障碍/痴呆临床表达的关系,并可能影响BBMs绝对浓度。
  • 上述因素不应妨碍AD的临床-生物学诊断。

关键数值与推荐

  • 当前证据和国际指南支持BBMs仅用于有症状的老年专科就诊者,不用于无症状个体。

临床怎么用

  • 将BBMs纳入老年综合评估框架,结合全面评估解读结果,以实现及时、准确和公平的临床-生物学诊断。
  • 在老年人群中解读BBMs时需考虑多病共存、慢性肾病、多重用药和衰弱等背景因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in Blood-Based Biomarkers (BBMs) are transforming the diagnostic landscape of Alzheimer Disease (AD), with plasma p-tau217 emerging as a highly accurate and scalable diagnostic marker of AD pathology. Across multiple analytical platforms, plasma p-tau217 has demonstrated consistently strong diagnostic performance for the detection of amyloid pathology. The interpretation of BBMs in older adults presents unique challenges due to the high prevalence of multimorbidity, chronic kidney disease, polypharmacy and frailty. Although these factors may influence absolute biomarker concentrations, current evidence suggests the diagnostic performance of p-tau217 remains largely preserved across diverse older populations when interpreted appropriately. Frailty may modify the relationship between AD pathology and clinical expression of mild cognitive impairment/dementia and may influence the absolute concentration of BBMs underscoring the importance of contextualising test results within a comprehensive assessment. Importantly, these factors should not preclude a clinical-biological diagnosis of AD. The clinical value of BBMs such as p-tau217 in older adults lies not in their use in isolation, but in their integration with a gerontologically attuned diagnostic pathway. Current evidence and international guidelines support the use of BBMs only in symptomatic older adults presenting to specialist services and not in asymptomatic individuals. This commentary reviews recent advances in BBM performance, emerging clinical guidelines, real-world evidence and potential diagnostic pitfalls relevant to older adults. We propose that incorporating BBMs within a Comprehensive Geriatric Assessment framework offers a pragmatic approach to achieving timely, accurate and equitable clinical-biological diagnosis whilst preserving the holistic, person centred principles of geriatric medicine.

来源:Age Ageing,查看原文。版权归原作者所有。

引用

  1. Dyer AH, Dolphin H, Roitto HM, et al. Recent breakthroughs in blood-based biomarkers of Alzheimer disease: opportunities and challenges in older adults. Age Ageing. 2026. PMID: 42476554. doi:10.1093/ageing/afag213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。